Evidence map›Paper›PMID 34993581›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2022

A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants?

Taís Menezes do Moinho, Sandro Leão Matos, Carla R O Carvalho

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taís Menezes do MoinhoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Sao Paulo, 05508000, Brazil.
Sandro Leão MatosDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Sao Paulo, 05508000, Brazil.
Carla R O CarvalhoDepartment of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Sao Paulo, 05508000, Brazil. croc@icb.usp.br.ORCID 0000-0001-5824-8656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome and, as such, is associated with obesity. With the current and growing epidemic of obesity, NAFLD is already considered the most common liver disease in the world. Currently, there is no official treatment for the disease besides weight loss. Although there are a few synthetic drugs currently being studied, there is also an abundance of herbal products that could also be used for treatment. With the World Health Organization (WHO) traditional medicine strategy (2014-2023) in mind, this review aims to analyze the mechanisms of action of some of these herbal products, as well as evaluate toxicity and herb-drug interactions available in literature.

Indexed as

Metabolic SyndromeNon-alcoholic Fatty Liver DiseaseHumansObesityPhytochemicalsPhytochemicalsFatty liverMetabolic syndromeNAFLDPhytochemicalsTraditional medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.